Autopsy report · NCT06341712
Effects of Maintenance Cabozantinib+BSC Versus BSC in Children and AYA With Osteosarcoma
Cause of deathOther
“The sponsor has decided to terminate the CabOSTar study due to ongoing recruitment challenges”
Life of this trial
- Registered 9 months before it started.
- Ran for about 1 year 3 months before it stopped.
- 10 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- Ipsen
- Sponsor type
- Industry
- Conditions
- Osteosarcoma; Osteosarcoma in Children; Osteosarcoma in Adolescents and Young Adults
- Interventions
- Cabozantinib; Best Supportive Care (BSC); Best Supportive Care (BSC)
- Participants
- 10
- Sites
- 16
- Countries
- Belgium, Canada, France, Germany, Italy, Netherlands, Poland, Spain, United Kingdom, United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.